REG - Ergomed plc - Change of Registered Office

ErgomedAnnouncement

15/06/2018 15:15

RNS Number : 6042R
Ergomed plc
15 June 2018
 


PRESS RELEASE
FOR IMMEDIATE RELEASE
 
 
Change of Registered Address
 
London, UK - 15 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that it has changed its registered office address with immediate effect to:
 
1 Occam Court
Surrey Research Park
Guildford
Surrey GU2 7HJ
United Kingdom
 
All other details remain the same including the Company's telephone/fax numbers and website (www.ergomedplc.com), which includes the information required by AIM Rule 26.
 
ENDS
 
 
 
Enquiries:
 



Ergomed plc


   Tel: +44 (0) 1483 503 205




Stephen Stamp (Chief Executive Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)








James Black (Joint Broker)


















N+1 Singer


Tel: +44 (0) 20 7496 3000




Aubrey Powel (Joint Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Philippa Gardner


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke












 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CROGGUPGQUPRGCA